Clinical Trials Logo

Cocaine-Related Disorders clinical trials

View clinical trials related to Cocaine-Related Disorders.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03266939 Not yet recruiting - Cocaine Dependence Clinical Trials

Rebalancing the Serotonergic System in Cocaine Dependence

Start date: September 2017
Phase: Phase 1
Study type: Interventional

In the United States, 1.5 million people abuse cocaine leading to a host of negative health and economic consequences, yet no FDA approved treatment exists. To develop effective treatments, the following must be considered: 1) do potential medications ameliorate brain disruptions associated with cocaine use? 2) are multiple, targeted treatments necessary? To meet these goals, innovative multi-modal neuroimaging will be used to determine whether rebalancing the serotonergic (5-HT) system reduces cocaine cue reactivity, impulsivity, and normalizes related neurochemistry and brain connectivity.

NCT ID: NCT03090269 Not yet recruiting - Clinical trials for Substance-Related Disorders

Methylphenidate for Cocaine Dependence

ANRS STIMAGO
Start date: December 31, 2017
Phase: Phase 2
Study type: Interventional

This phase II pilot study aims at evaluating the benefits and the risks of methylphenidate (Concerta®) for the treatment of cocaine/crack dependence in terms of cocaine/crack use reduction and adverse events.

NCT ID: NCT03025321 Not yet recruiting - Cocaine Addiction Clinical Trials

Effects of Repetitive tDCS on Relapse in Cocaine Addiction: EMA Study

Start date: January 2017
Phase: N/A
Study type: Interventional

Repetitive bilateral (left cathodal/ right anodal) transcranial Direct Current Stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC) seems to reduce craving and relapse risk. However, little is known about the relapse rates in cocaine addiction after tDCS, despite the need for new treatment interventions to reduce the high relapse rates in cocaine addiction. The investigators aim to explore the effects of repetitive tDCS in a larger sample (N=80) of cocaine addicted patients on number of relapse days after three months. In addition, the underlying working mechanism will be explored (e.g. cognitive control functioning). Ecological momentary assessment (EMA) will be used to measure relapse, craving and mood since retrospective self-reports seem to be less reliable in this respect.

NCT ID: NCT02915341 Not yet recruiting - Clinical trials for Cocaine-Related Disorders

Towards Detecting Cocaine Use Using Smartwatches in the NIDA Clinical Trials Network

AutoSense
Start date: December 2016
Phase: N/A
Study type: Observational

The overall objective of this study is to extend previous work in the development of methods to automatically detect the timing of cocaine use from cardiac interbeat interval and physical activity data derived from wearable, unobtrusive mobile sensor technologies. The specific objectives of this protocol are to characterize under which conditions high quality continuous interbeat interval data and physical activity data can be obtained from a specially developed smartwatch device in the natural field setting among a population of cocaine users. In addition to identifying common failure scenarios and understanding wearability/usage patterns when collecting interbeat interval from smartwatches, this study will extend previous work in the detection of cocaine use via interbeat interval and physical activity data that were previously obtained from wearable chestband sensors. Information from this study will contribute toward the adaptation of the investigators' existing computational model for detecting cocaine use via the chest sensors, so it can be applied to the interbeat and physical activity data obtained from less obtrusive smartwatches.

NCT ID: NCT01319214 Not yet recruiting - Cocaine Addiction Clinical Trials

Reducing Drug Craving Memories

Start date: March 2011
Phase: N/A
Study type: Interventional

The primary objective is to investigate the potential ability of Inderal (propranolol hydrochloride) to diminish the reconsolidation of motivationally potent drug-related cues in cocaine dependent participants. If effective in this laboratory model, Inderal may have clinical efficacy.